LITERATURE REVIEW

Profile of neurological manifestations in patients with COVID-19: Review of the literature published during the first six months of the pandemic

Perfil de manifestaciones neurológicas en pacientes con COVID-19: revisión de la literatura publicada durante los primeros seis meses de la pandemia

C. Daza-Latorre 1, D. Echeverria-Palacio 1, S. Albornoiz 1, J. Argothy 1, L. Albornoz 1, M. Ocampo 2, J. Vera 1

1 Universidad El Bosque - Faculty of Medicine - Bogotá D.C. - Colombia.
2 Universidad del Rosario - School of Medicine and Health Sciences - Universidad del Rosario Neuroscience Group - Bogotá D.C. - Colombia.

Abstract

Introduction: Several studies describing different neurological manifestations in patients with COVID-19 were published during the first six months of the pandemic.

Objective: To collect and synthesize the scientific evidence published within the first six months after COVID-19 was declared a pandemic on neurological manifestations in patients infected with SARS-CoV-2, as well as their prevalence and variations in specific populations.

Materials and methods: A literature search was conducted in PubMed/MEDLINE using the following search strategy: any study describing neurological manifestations in COVID-19 patients; publication period: March 11-August 31, 2020; publication language: English; search terms and search equation: (“COVID-19”) AND “Neurologic Manifestations”).

Results: The initial search yielded 388 records, of which 79 met the eligibility criteria and were included for full analysis. Most studies were case reports (50.63% individual case reports and 18.99% case series), while only 30.38% were analytical studies, with cross-sectional studies being the most common (n=25). The most frequently described neurological manifestation was smell and/or taste disorder (43.04%), followed by peripheral neuropathy (20.25%), seizures (8.86%), encephalitis (7.59%), and delirium (5.06%). Other manifestations reported to a lesser extent included headache, myositis, stroke, and transverse myelitis.

Conclusion: Most neurological manifestations reported have a favorable progress, occur in young patients without any comorbidity, and are unrelated to the severity of the disease. Other manifestations such as delirium and epileptic seizures occur more frequently in people with a history of dementia or epilepsy, respectively. Finally, some manifestations such as Guillain-Barré syndrome and stroke may cause several sequelae.

Resumen

Introducción. Durante los primeros seis meses de la pandemia por COVID-19 se publicaron varios estudios que describen diferentes manifestaciones neurológicas en pacientes con esta enfermedad.

Objetivo. Recopilar y sintetizar evidencia científica publicada en los seis meses posteriores a la declaración de la pandemia por COVID-19 sobre manifestaciones neurológicas en pacientes infectados con SARS-CoV-2, así como sus variaciones y frecuencia en poblaciones específicas.


Resultados. La búsqueda inicial arrojó 388 registros, de los cuales 79 cumplieron los criterios de elegibilidad. La mayoría de los estudios fueron reportes de caso (50.63% reportes individuales de caso y 18.99%, series de casos), mientras que solo 30.38% fueron estudios analíticos, siendo los estudios transversales los más frecuentes (n=25). La manifestación neurológica descrita con mayor frecuencia fue la alteración del olfato y/o gusto (43.04%), seguida de neuropatía periférica (20.25%), convulsiones (8.86%), encefalitis (7.59%) y delirium (5.06%). Otras manifestaciones reportadas en menor proporción fueron cefalea, miopatía, accidente cerebrovascular (ACV) y mielitis transversa.

Conclusión. La mayoría de las manifestaciones neurológicas de la COVID-19 reportadas tienen una evolución favorable, ocurren en pacientes jóvenes sin comorbilidades y no tienen relación con la severidad de la enfermedad. Otras manifestaciones, como delirium y crisis epilépticas, se presentan con mayor frecuencia en población con antecedentes de demencia o epilepsia, respectivamente. Por último, algunas manifestaciones como el síndrome de Guillain-Barré y los ACV pueden causar secuelas.
**Introduction**

With the emergence of MERS-CoV in 2012 and SARS-CoV in December 2019, global attention has focused on the coronavirus family, since these are major pathogens that cause respiratory tract infections of variable severity. The current public health crisis began in late 2019 with an unexplained increase in cases of pneumonia of unknown origin in Wuhan, China, which quickly spread to other cities and countries. Subsequently, in January 2020, SARS-CoV-2 was identified as the causative microorganism of this new disease, which was named Coronavirus Disease 2019 (COVID-19), and declared as a public health emergency of international concern on January 30 and as a pandemic on March 11, 2020, by the World Health Organization (WHO) due to its high pathogenic potential and rapid spread. Since its detection in China in December 2019 until March 9, 2021, 116,736,437 confirmed cases of COVID-19 were reported globally, of whom 2,593,285 died.

At present, there is increasing research reporting that coronavirus infections do not only affect the respiratory tract. In this regard, it has been pointed out that central nervous system involvement may take place in susceptible individuals and contribute to the increased morbidity and mortality of severe COVID-19. Accordingly, it has been established that this disease not only leads to respiratory involvement, but can also affect the nervous system.

As reported by Losy et al., the first retrospective study on neurological symptoms in COVID-19, conducted in China by Mao et al., found that 36.4% of the 214 COVID-19 patients evaluated had neurological manifestations such as dizziness, headache, altered consciousness, impaired smell and taste, stroke, seizures, ataxia, and musculoskeletal injury, among others. Furthermore, other studies have reported the occurrence of anosmia, seizures, acute ischemic stroke, viral meningoencephalitis, acute necrotizing encephalopathy, acute flaccid paralysis, post/para-infectious syndromes, and corticospinal weakness in patients with severe COVID-19.

Although the pathophysiological mechanisms underlying the involvement of the nervous system during SARS-CoV-2 infection have not been fully elucidated, evidence suggests that this disease could be a multifactorial phenomenon in which processes such as direct involvement, autoimmune factors, inflammation (cytokine storm), anterograde or retrograde axonal transport, pharmacological side effects, metabolic alterations, and neuropathy in the critically ill patient, among others, stand out.

Taking into account the above and based on the need to offer patients with COVID-19 a more comprehensive approach to establish a diagnosis and timely treatment, the objective of this literature review was to collect and synthesize scientific evidence published within six months after the declaration of the COVID-19 pandemic on neurological manifestations in patients infected with SARS-CoV-2, as well as their variations and frequency in specific populations.

**Materials and methods**

A literature review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search was performed in PubMed/Medline using the following search strategy: study types: any type describing neurologic manifestations in patients with COVID-19; publication period: March 11 to August 31, 2020; publication language: English; search terms and equation: (“COVID-19”) AND “Neurologic Manifestations”) (MeSH terms).
The search, identification and selection process is described in detail below (Results section). All authors contributed to the review of the articles identified in the literature search, led by DLMA and EPCM, specialists in neurology and child neurology, respectively. It should be noted that during the title and abstract review stage, studies that did not address the topic of interest of the review were discarded. Moreover, during the full-text reading stage, studies were excluded if it was not possible to access the full text using institutional resources, as well as the following study types: narrative and systematic reviews, meta-analyses, and reflection articles. It is also necessary to point out that the review protocol was not registered.

The following data were extracted from the analysis of the articles included in the review: main neurological manifestation, secondary complications reported, sociodemographic variables of the patients, presence of comorbidities, and COVID-19 severity (presence of symptoms, requirement for hospitalization, etc.).

Data collected from individual case reports and case series were grouped by reported neurological manifestation and variables of interest to this study (age, sex, presence of comorbidities, and COVID-19 severity), and summarized in a table (available in the Results section). In said table, qualitative variables are presented as relative frequencies and medians with their respective interquartile ranges for qualitative and quantitative variables, respectively.

Results

The initial search yielded 388 records, of which 216 were excluded during the title and abstract review stage because they did not address the topic of interest for the study: 10 were excluded during the full-text reading stage because of full text unavailability and 83 were excluded because of the type of study, resulting in the inclusion of 79 studies for full analysis. The search and article selection flowchart is presented in Figure 1.

![Figure 1. Article search and selection flowchart. Source: Own elaboration.](https://doi.org/10.15446/revfacmed.v70n4.94550)

Out of the 79 included studies, 50.63% were case reports, 18.99% were case series, and 30.38% were analytical studies, the majority of which were cross-sectional studies (n=20), followed by cohort studies (n=2), and case-control studies (n=2). The most
frequently reported COVID-19-associated neurological manifestation was impaired sense of smell and/or taste (43.04%), followed by peripheral neuropathy (20.25%), seizures (8.86%), encephalitis (7.59%), and delirium (5.06%). Other manifestations less frequently described were headache, myositis, stroke, and transverse myelitis (Table 1). In addition, most of the studies were published in the United States (24.05%), Italy (13.92%), and Spain and the United Kingdom (8.86% each).

Demographic characteristics, presence of comorbidities, and COVID-19 severity according to neurological manifestation described in individual case reports and case series are presented in Table 2.

Table 1. Distribution of the most common neurological manifestations reported in COVID-19 patients by publication type.

<table>
<thead>
<tr>
<th>Neurological manifestation</th>
<th>Case report (individual) (n=40)</th>
<th>Case series (n=15)</th>
<th>Cross-sectional study (n=20)</th>
<th>Cohort study (n=2)</th>
<th>Case-control studies (n=2)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smell and/or taste impairment</td>
<td>8</td>
<td>6</td>
<td>18</td>
<td>0</td>
<td>2</td>
<td>34</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>11</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>16</td>
</tr>
<tr>
<td>Seizures</td>
<td>5</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Encephalitis</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Delirium</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Other *</td>
<td>8</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>12</td>
</tr>
</tbody>
</table>

* Case report consisting of three cases with stroke; series of two cases of vasovagal syncope; two individual case reports of rhabdomyolysis; two individual case reports of visual impairment; an individual case report of ataxia, headache, and decreased consciousness. Source: Own elaboration.

Table 2. Summary of individual cases and case series.43-50

<table>
<thead>
<tr>
<th>Impaired sense of smell and/or taste</th>
<th>Peripheral neuropathy</th>
<th>Seizures</th>
<th>Delirium</th>
<th>Encephalitis</th>
<th>Other *</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases</td>
<td>27</td>
<td>20</td>
<td>10</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Women</td>
<td>63%</td>
<td>68%</td>
<td>50%</td>
<td>25%</td>
<td>83%</td>
</tr>
<tr>
<td>Age in years (IQR)</td>
<td>38 (27-53)</td>
<td>49 (35-66)</td>
<td>66.5 (47.7-76)</td>
<td>74.5 (68-83)</td>
<td>49 (29-67.5)</td>
</tr>
<tr>
<td>Presence of comorbidities</td>
<td>18%</td>
<td>50%</td>
<td>50%</td>
<td>75%</td>
<td>50%</td>
</tr>
<tr>
<td>COVID-19 severity</td>
<td>80%</td>
<td>62%</td>
<td>60%</td>
<td>50%</td>
<td>33%</td>
</tr>
<tr>
<td>Mild</td>
<td>8%</td>
<td>63%</td>
<td>30%</td>
<td>25%</td>
<td>17%</td>
</tr>
<tr>
<td>Moderate</td>
<td>12%</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
<td>50%</td>
</tr>
</tbody>
</table>

* Other: case report of three stroke cases; series of two cases of vasovagal syncope; two individual case reports of rhabdomyolysis; two individual case reports of visual impairment; an individual case report of ataxia, headache, and decreased consciousness. wIQR: interquartile range. Source: Own elaboration.

In addition, Table 3 presents the objective, sample, population characteristics, severity of SARS-CoV-2 infection, primary and secondary neurological manifestations, and findings of all analytical studies (descriptive, cross-sectional, case-control, and cohort) on neurological manifestations in patients with COVID-19.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Objective</th>
<th>n</th>
<th>Population characteristics</th>
<th>Severity of SARS-CoV-2 infection</th>
<th>Primary neurological manifestation</th>
<th>Additional neurological manifestations</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaira et al.</td>
<td>To monitor olfactory and gustatory dysfunctions in COVID-19 patients and determine their association with disease severity</td>
<td>106</td>
<td>Age: 49.6 (IQR: 43-55.2) Female: 50% Comorbidities: - None: 69.8% - One: 18.9% - Two: 6.6% - More than two: 4.7%</td>
<td>Hospitalized: 28.3%</td>
<td>Initial assessment (T0): - Olfactory dysfunction: 67% - Gustatory dysfunction: 71% Tenth day of evaluation (T1): - Anosmia: 15.1% - Severe hyposmia: 27.4% - Normal taste: 43.4% 20-day follow-up (T2): - Normal smell: 44.3% - Severe olfactory disorder: 19.7% - Normal taste: 52.8%</td>
<td>NR</td>
<td>- Direct proportional relationship between the severity of olfactory dysfunction and fever in T2 ($p=0.05$). - Direct proportional relationship between the severity of gustatory dysfunction and fever in both T1 and T2 ($p=0.01$ and $p&lt;0.001$). - Direct proportional relationship between involvement severity based on gustatory scores and oxygen saturation. ($p&lt;0.001$). - Significant correlation between the severity of olfactory dysfunction and the need for hospitalization. (OR=3.7; $p&lt;0.005$).</td>
</tr>
<tr>
<td>Fjaeldstad</td>
<td>To establish the temporal dynamics of improvement and recovery from sudden olfactory and gustatory loss in patients with suspected or confirmed diagnosis of COVID-19</td>
<td>109</td>
<td>Age (average): 39.4 Women: 72.48%</td>
<td>Outpatients: 100%</td>
<td>- Loss of smell and taste: 87.15% - Loss of smell only: 4.59% - Loss of taste only: 8.26%</td>
<td>TRIGEMINAL DEFICIT (ALTERATIONS OF OTHER ORAL SENSATIONS SUCH AS BURNING, COOLING, OR TINGLING): 24.77%</td>
<td>- 44% of the patients completely recovered from the loss of smell, while 28% had no improvement. - 50% of the patients experienced complete recovery of taste loss, while 20% had no improvement. - Patients who experienced improvement in olfactory function were younger. ($p=0.0248$).</td>
</tr>
<tr>
<td>Somekh et al.</td>
<td>To evaluate differences in smell and taste sensations in children and adults and to determine their correlation with angiotensin-converting enzyme 2 expression</td>
<td>73</td>
<td>Age groups: - Children (5-17 years): 31 - Adults ($≥ 18$ years): 42</td>
<td>Outpatients: 100%</td>
<td>Smell or taste impairment: 51% (children: 25.8%; adults: 71.4%)</td>
<td>NR</td>
<td>- Smell or taste impairment was less frequent in children (risk ratio: 0.39, 95% CI: 0.23-0.65; $p=0.00014$). - Smell or taste impairment was more severe in older adults than in younger adults (18-25 years old; $p=0.038$). - Relationship between the degree of sensory loss and the relative expression of angiotensin-converting enzyme 2 (Pearson’s Coefficient: 0.95; $p=0.05$).</td>
</tr>
<tr>
<td>Jalessi et al.</td>
<td>To find out the frequency of olfactory impairment and its outcome in hospitalized COVID-19 patients</td>
<td>92</td>
<td>Age (mean): 52.94±13.25 years old Female: 32.6%. Frequent comorbidities: - Diabetes mellitus: 23.9%. - High blood pressure: 22.8% - Allergies: 17.4% - Heart disease: 15%</td>
<td></td>
<td>- Inpatients: 100% - Mild pneumonia: 78.3% - Moderate pneumonia: 21.7% Olfactory impairment: 23.91%</td>
<td>Headache: 9.8%</td>
<td>- No significant association was found between sinonasal symptoms and olfactory loss, suggesting that mechanisms other than upper respiratory tract involvement are responsible for olfactory loss. - A significant difference was found between pneumonia severity and age ($p=0.002$).</td>
</tr>
</tbody>
</table>
### Table 3. Summary of descriptive, cross-sectional, case-control, and cohort studies on neurological manifestations in COVID-19 patients.66-89 (continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Objective</th>
<th>n</th>
<th>Population characteristics</th>
<th>Severity of SARS-CoV-2 infection</th>
<th>Primary neurological manifestation</th>
<th>Additional neurological manifestations</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kosugui et al.66 †</td>
<td>To characterize patients with sudden olfactory impairment during the COVID-19 pandemic and their recovery</td>
<td>253 (79.2% tested positive for COVID-19)</td>
<td>Patients with positive COVID-19 test:  - Age (median): 36 (IQR: 31-44)  - Female: 53.1%  - Comorbidities: 32.4%  Patients with negative COVID-19 test:  - Age (median): 35.5 (IQR: 30.25-45.25)  - Female: 68.4%  - Comorbidities: 39.5%</td>
<td>NR</td>
<td>Olfactory dysfunction self-reporting: 100%</td>
<td>- Patients with COVID-19 had a lower rate of olfactory dysfunction recovery than those without COVID-19 (52.6% vs. 70.3%; p=0.05).  - COVID-19 patients had a longer recovery time than those without COVID-19 (15 days vs. 10 days; p&lt;0.0006).  - Patients with COVID-19 and sudden hyposmia had a higher recovery rate than those with COVID-19 and anosmia (p=0.04).</td>
<td></td>
</tr>
<tr>
<td>Chary et al.67 †</td>
<td>To determine the prevalence of olfactory and taste dysfunction in patients with COVID-19, as well as short-term recovery.</td>
<td>115</td>
<td>Age (mean): 47 (range: 20-83 years)  Female: 70%</td>
<td>Hospitalization: 24%.  ICU: 4%.</td>
<td>- Olfactory or taste disorders: 70%  - Anosmia and hypogeusia: 33%  - Anosmia and ageusia: 32%  - Isolated anosmia: 15%</td>
<td>Headache: 54%</td>
<td>Olfactory or gustatory disorders were more prevalent in young patients (p=0.003) and in women (p=0.027).  - There was a significant difference in the need for hospitalization (p=0.016) and ICU (p=0.043) between patients with olfactory and taste disorders and those without these disorders.  - On day 15, 64% of patients achieved complete recovery and 33% incomplete recovery.  - The median recovery time was 15 days (range: 4-27 days) from the onset of olfactory or taste impairment symptoms.</td>
</tr>
<tr>
<td>Haehner et al.68 †</td>
<td>To investigate the frequency of olfactory loss in an outpatient population attending a coronavirus testing center during a 2-week period</td>
<td>500 With positive COVID-19 test: 34</td>
<td>Age (median): 41.3 years (range: 18-86 years)  Female: 54.6%</td>
<td>Outpatient: 100%</td>
<td>64.7% of COVID-19 patients reported olfactory and gustatory loss</td>
<td>NR</td>
<td>- COVID-19 patients with olfactory loss were significantly younger than those without smell loss (p=0.04) and had less severe symptoms.  - Excluding patients with blocked nose, the symptom “sudden smell loss” had a high specificity (90%) and a sensitivity of 65%, with a positive predictive value of 63% and a negative predictive value of 97% for COVID-19.  - Patients without COVID-19 experienced nasal obstruction more frequently than those with COVID-19 (p=0.001).</td>
</tr>
<tr>
<td>Dell’Era et al.69 †</td>
<td>To determine the prevalence and severity of smell and taste disorders in patients with COVID-19. Secondly, to investigate the time of onset of these symptoms and their recovery time</td>
<td>335</td>
<td>Age (median): 50 years (IQR: 40-59.5).  Female: 45.9%.  Comorbidities:  - Cardiac: 11.8%.  - Respiratory: 11.3%  - Allergic or nasosinusal: 10.7%</td>
<td>Asymptomatic or with mild or moderate symptoms: 100%</td>
<td>- Smell and/or taste disorders: 70%  - Smell impairment: 66.76%  - Taste impairment: 65.35%</td>
<td>NR</td>
<td>- Smell impairment prior to diagnosis of COVID-19 occurred in 54% of cases.  - Smell impairment was the first symptom of COVID-19 in 8.7% of the cases.  - 49.5% of patients with complete smell loss fully recovered after 14 days.  - The median recovery time was 10 days.</td>
</tr>
</tbody>
</table>
Table 3. Summary of descriptive, cross-sectional, case-control, and cohort studies on neurological manifestations in COVID-19 patients.66-97 (continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Objective</th>
<th>n</th>
<th>Population characteristics</th>
<th>Severity of SARS-CoV-2 infection</th>
<th>Primary neurological manifestation</th>
<th>Additional neurological manifestations</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boscolo-Rizzo et al.†</td>
<td>To estimate the prevalence of smell and taste impairment in people with a high risk of SARS-CoV-2 infection</td>
<td>296 people in contact with COVID-19 patients (positive COVID-19 test: 18.5%; negative COVID-19 test: 22.6%; no test: 59.1%)</td>
<td>NR</td>
<td>NR</td>
<td>Taste or smell impairment in contacts with positive COVID-19 test: 34 contacts, 63% (95%CI: 48.7-75.7). Taste or smell impairment in contacts without COVID-19 test: 39 contacts, 22.3% (95%CI: 16.4-29.2).</td>
<td>NR</td>
<td>Contacts who tested positive for COVID-19 had significantly more symptoms (fever, cough, respiratory problems, smell or taste impairment, and other symptoms) than those with a negative COVID-19 test or no test.</td>
</tr>
<tr>
<td>Lechien et al.†</td>
<td>To investigate the frequency of olfactory dysfunction in patients with mild COVID-19 as reported in a questionnaire and evaluated with an objective psychophysical test (SNOT-22 and Sniffin’ Sticks test)</td>
<td>86</td>
<td>Age (mean): 41.7±11.8 years old  Female: 65.1% Most frequent comorbidities:  - Gastroesophageal reflux disease: 10.5%  - Asthma: 5.8%  - Rhinitis: 5.8%</td>
<td>Mild</td>
<td>Reported:  - Anosmia: 61.4%  - Objective:  Anosmia: 47.7%  - Hypophosmia: 14%</td>
<td>NR</td>
<td>Headache: 60%</td>
</tr>
<tr>
<td>Vaira et al.†</td>
<td>To determine the frequency olfactory and gustatory function impairment in COVID-19 patients</td>
<td>345 (161 patients in quarantine at home and 184 hospitalized patients)</td>
<td>Age (mean): 48.5 ± 12.8 years (range: 23-88 years)  Female: 57.7%</td>
<td>- Asymptomatic: 2.9%  - Mild: 48.7%  - Moderate: 40.6%  - Severe: 7.8%</td>
<td>Chemosensitive disorders: 256, 74.2% (olfactory impairment: 94.14%; taste impairment: 60.54%). Duration of chemosensitive symptoms:  - &lt;7 days: 74.6%  - &gt;7 days: 24.4% Days from COVID-19 symptom onset: 14.8±7.4 (range: 2-35 days)</td>
<td>NR</td>
<td>- There was no significant correlation between the presence or severity of chemosensitive disorders and severity of COVID-19.  - Patients who reported a duration of olfactory and gustatory symptoms greater than 7 days had an increased risk of developing a moderate (relative risk: 1.12) or severe COVID-19 (relative risk: 2.33).</td>
</tr>
<tr>
<td>Coelho et al.††</td>
<td>To describe the presentation, progression, testing status, and prognosis in patients with recent acute changes in smell or taste, regardless of the presence of COVID-19</td>
<td>220 (42.3% were positive for COVID-19 or the diagnosis was made by a physician)</td>
<td>Age (mean): 42.8±13.5 years  Female: 78.2%  Most frequent comorbidities:  - Seasonal allergies: 34.5%.  - Cardiovascular disease: 12.3%  - Chronic respiratory conditions (asthma, chronic obstructive pulmonary disease): 8.2%  - History of head trauma or brain injury: 4.5%</td>
<td>NR</td>
<td>Self-report of changes in smell or taste: 100%. Changes in smell or taste as the only or first symptom: 37% (65.1% with changes in both senses, 26.5% with changes only in smell, and 8.4% with changes only in taste)</td>
<td>NR</td>
<td>Headache: 81.7% in patients with COVID-19 diagnosis.  - 61.4% in patients with no COVID-19 diagnosis  - The most common COVID-19 symptoms in these patients were fatigue or weakness, headache, muscle pain, cough, fever, nasal congestion, diarrhea, and shortness of breath.  - Patients with changes in only one sense are less likely to be tested or diagnosed than patients with other symptoms (p=0.047).  - Males (p=0.020) and patients with cardiovascular disease (p=0.041) have a higher risk of presenting changes in smell or taste as their first or only symptom.  - No significant differences were found between patients with a COVID-19 diagnosis and patients without a diagnosis in terms of symptoms nasal congestion and runny nose.</td>
</tr>
</tbody>
</table>
Table 3. Summary of descriptive, cross-sectional, case-control, and cohort studies on neurological manifestations in COVID-19 patients.16-19 (continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Objective</th>
<th>n</th>
<th>Population characteristics</th>
<th>Severity of SARS-CoV-2 infection</th>
<th>Primary neurological manifestation</th>
<th>Additional neurological manifestations</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speth et al.18 †</td>
<td>To determine the prevalence, severity and timing of olfactory dysfunction with respect to other sinonasal and pulmonary symptoms in patients with COVID-19</td>
<td>103</td>
<td>Age (mean): 46.8±15.9 years old</td>
<td>Female: 51.5%</td>
<td>Most frequent comorbidities: - Allergic rhinitis: 35%. - Asthma: 12.6%</td>
<td>Inpatients: 22.33%.</td>
<td>- Olfactory dysfunction: 61.2% (95%CI: 51.5-70.0)</td>
</tr>
<tr>
<td>Paderno et al.20 †</td>
<td>To determine the prevalence and rate of recovery of olfactory and gustatory dysfunction in inpatients and outpatients with COVID-19</td>
<td>508</td>
<td>Age (mean): 55±15 years</td>
<td>Female: 44%</td>
<td>Comorbidities: - Inpatients: 78.7% - Outpatients: 33.3%</td>
<td>Most frequent comorbidities in inpatients: - High blood pressure: 47.5% - Obesity: 20.3% - Diabetes mellitus: 20% - Cardiomyopathy: 16.3%</td>
<td>- Inpatients: 58% (n=295)</td>
</tr>
<tr>
<td>Lee et al.21 †</td>
<td>To determine the prevalence and duration of anosmia and ageusia in COVID-19 patients</td>
<td>3191</td>
<td>Age (median): 44.0 (IQR: 25-58)</td>
<td>Female: 63.6%</td>
<td>Frequent comorbidities: - High blood pressure: 9.8% - Diabetes mellitus: 5.1%</td>
<td>- None: 51.4%</td>
<td>- Smell only: 14.4%</td>
</tr>
<tr>
<td>Hopkins et al.22 †</td>
<td>To characterize patients reporting in a survey the onset of smell and taste disturbances during the COVID-19 pandemic and to determine early recovery rates</td>
<td>382</td>
<td>(only 3.92% had a COVID-19 test, of which 80% had a positive result).</td>
<td>- Age (median): 30-39 years</td>
<td>Female: 73%</td>
<td>- Smell and taste disorders:</td>
<td>NR</td>
</tr>
<tr>
<td>Vaira et al.23 †</td>
<td>To objectively assess smell and taste dysfunction in patients with COVID-19 by means of physical-psychological tests</td>
<td>72</td>
<td>Age (mean): 49.2±13.7 (range: 26-90)</td>
<td>Female: 62.5%</td>
<td></td>
<td>- Inpatients: 34.72%.</td>
<td>- Outpatients: 65.28%</td>
</tr>
</tbody>
</table>
## Table 3. Summary of descriptive, cross-sectional, case-control, and cohort studies on neurological manifestations in COVID-19 patients.66-97 (continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Objective</th>
<th>n</th>
<th>Population characteristics</th>
<th>Severity of SARS-CoV-2 infection</th>
<th>Primary neurological manifestation</th>
<th>Additional neurological manifestations</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yan et al.66 †</td>
<td>To determine and compare the prevalence of chemosensory impairment in patients with and without COVID-19</td>
<td>262</td>
<td>Age: 83.74% ≤49 years old; Female: 49.2%</td>
<td>Inpatients: - With positive COVID-19 test: 7% (n=4/58); - Negative COVID-19 test: 7% (n=14/200)</td>
<td>Loss of smell: - Positive COVID-19 test: 68%; - Negative COVID-19 test: 16%; Taste impairment: - Positive COVID-19 test: 71%; - Negative COVID-19 test: 17%</td>
<td>Headache: 66.1%</td>
<td>- Smell and taste impairment was strongly associated with having COVID-19 (anosmia: aOR=10.9, 95%CI: 5.08-23.5; dysgeusia: aOR=10.2, 95%CI: 4.74-22.1). - 74% of patients reporting COVID-19-associated loss of smell reported recovery with clinical resolution of the disease.</td>
</tr>
<tr>
<td>Liguori et al.67 †</td>
<td>To identify and quantify the occurrence of neurological symptoms in hospitalized patients with COVID-19 infection who underwent an anamnestic interview</td>
<td>103</td>
<td>Age (mean): 55±14.65</td>
<td>Inpatients Non-severe COVID-19</td>
<td>Sleep disturbance: 51%; - Dysgeusia: 46.60%; - Hyposmia: 38.83%; - Headache: 38.83; - Depression: 37.86; - Anxiety: 33.01%; - Sleep disturbance: 33.01%; - Fatigue: 32.04%; - Dizziness: 26. 21%; - Muscle ache: 24.27%; - Confusion: 22.33%</td>
<td>NR</td>
<td>- 91.3% of patients reported at least one neurological symptom. - Women reported neurological symptoms more frequently than men (hyposmia: p=0.0047; dysgeusia: p=0.0028; headache: p=0.0047; dizziness: p=0.0431; paresthesia: p=0.0035; daytime sleepiness: p=0.0061; muscle ache: p=0.0033). - Muscle pain and daytime sleepiness are more frequent in patients interviewed on the first and second day of hospitalization (p=0.004 and p=0.01, respectively). - Sleep impairment is more frequent in the group of patients interviewed after more than 7 days of hospitalization (p=0.03).</td>
</tr>
<tr>
<td>Menni et al.68 †</td>
<td>To identify the symptoms most predictive of COVID-19 in the US and English population with a COVID-19 test who reported information on a smartphone-based app</td>
<td>18 401</td>
<td>Age: 41.25±12.18 in patients with a positive COVID-19 test and 41.87±12.14 in those with a negative test; Female: 71.88%</td>
<td>Loss of smell and taste: - UK: 64.76% in patients with a positive COVID-19 test and 22.68% in those with a negative test; - US: 67.49% in patients with a positive COVID-19 test and 17.33% in those with a negative test</td>
<td>Delirium - UK: 17.87% in patients with a positive COVID-19 test and 13.25% in those with a negative test; - US: 23.55% in patients with a positive COVID-19 test and 23.47% in those with a negative test</td>
<td>NR</td>
<td>- Loss of smell or taste occurred in a higher proportion in patients with a positive COVID-19 test (65.03% vs. 21.71%; OR=6.74; 95%CI: 6.31-7.21; p&lt;0.0001). - According to the multivariate model, it was predicted that 140,312 (17.42%) of the participants were likely to have COVID-19.</td>
</tr>
<tr>
<td>Carignan et al.69 †</td>
<td>To confirm whether anosmia and dysgeusia are specific symptoms in patients with a positive COVID-19 test</td>
<td>268</td>
<td>Age (median): 57.1 (IQR 41.2-64.5)</td>
<td>Inpatients: 2 positive for COVID-19 and 1 control</td>
<td>Anosmia: - COVID-19 patients: 51.5%; - Control patients: 4.5%; Dysgeusia: - COVID-19 patients: 63.4%; - Control patients: 6.7%; Anosmia and dysgeusia: - COVID-19 patients: 64.9%; - Control patients: 8.2%</td>
<td>Headache: - COVID-19 patients: 64.9% - Control patients: 46.3%; Muscle pain: - COVID-19 patients: 56.7%; - Control patients: 21.6%</td>
<td>Associations were found between the following symptoms and having COVID-19: - Crude analysis: - Dysgeusia: OR=16.2 (95%CI: 6.6-40.0). - Anosmia: OR=32.5 (95%CI: 8.0-132.7). - Dysgeusia+anosmia: OR=20 (95%CI: 7.3-54.6). - Headache: OR=2.9 (95%CI: 1.3-3.4). - Adjusted analysis: - Anosmia, dysgeusia, or both: aOR=62.9 (95%CI: 11.0-359.7). - Muscle pain: aOR=7.6 (95%CI: 1.9-29.9).</td>
</tr>
</tbody>
</table>


9/19
### Table 3. Summary of descriptive, cross-sectional, case-control, and cohort studies on neurological manifestations in COVID-19 patients.66-89 (continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Objective</th>
<th>n</th>
<th>Population characteristics</th>
<th>Severity of SARS-COV-2 infection</th>
<th>Primary neurological manifestation</th>
<th>Additional neurological manifestations</th>
<th>Findings</th>
</tr>
</thead>
</table>
| Tsivgoulis et al.67  | To objectively assess olfactory dysfunction in hospitalized patients with COVID-19 (using two instruments: Q-SIT and SNOT-22) | 22 cases (patients with COVID-19) and 22 controls, matched for age and sex | Average age: 55±10
- Female: 43%
- Most frequent comorbidities:
  - High blood pressure: 57%
  - Diabetes mellitus: 22%
  - Atrial fibrillation: 13%
  - Ischemic cardiomyopathy: 13% | Inpatients (moderate COVID-19 cases with no reports of intubation requirement or death) | Some degree of olfactory dysfunction: 77% in COVID-19 patients and 36% in controls
Mean Q-SIT:
- Cases: 2 (IQR: 1-2)
- Controls: 3 (IQR: 2-3)
Nasal congestion (SNOT 22): 18.75% of patients with anosmia (n=16) | - NR | - Moderate olfactory dysfunction was found in almost three quarters of COVID-19 patients.
- Olfactory dysfunction was more prevalent in COVID cases than in control patients (p=0.006).

| Helms et al.73 ** | To describe the prevalence of delirium and other neurological symptoms in COVID-19 patients treated in an intensive care unit | 140     | Age (median): 62 years (IQR: 52-70)
- Female: 28.6%
- Most common comorbidities:
  - Cardiovascular disease: 50.0%
  - Diabetes: 15%
  - Hematopathology/malignancy: 15%
  - Respiratory disease: 15.7% | Severe: 100% | Neurological test alteration: 84.3%. Delirium with attention, awareness, and cognition disturbances: 84.3% | NR | - Patients with delirium and/or abnormal neurological test result were on invasive mechanical ventilation longer than those with a normal neurological test (14 days [IQR: 10-25] vs. 9 days [IQR: 5-17]; p=0.001).
- Length of intensive care unit stay was longer in patients with delirium and/or abnormal neurological test result than in those with a normal neurological test (15 days [IQR: 11-25] vs. 10 days [IQR: 6-21]; p=0.017).

| Trigo et al.71 ** | To analyze which symptoms and laboratory abnormalities are associated with the presence of headache in hospitalized patients with COVID-19 and to assess whether patients with a headache have a higher adjusted in-hospital risk of mortality | 576     | Age (mean): 67.2±14.7
- Female: 43.3%
- Most common comorbidities:
  - High blood pressure: 52.1%
  - Cardiac disorders: 26.7%
  - Pulmonary diseases: 25%
  - Diabetes: 19.6% | Inpatients: 100% | Headache: 23.7% (As first symptom: 26.0% [within the first 24 hours: 38.5%; within the first 48 hours: 62.5%; within the first 72 hours: 74.0%]) | - Anosmia: 25.3%
- Myalgia 24.1% | - Having anosmia, muscle pain or fever and being female were associated with an increased risk of headache in COVID-19 patients.
- The presence of headache was more frequent in women (p=0.019) and patients with a history of headache (p=0.019).
- Headache was less frequent in patients with cardiac disorders (p=0.001) and hypertension (p=0.001).
- Patients with headache had a better score on the modified Rankin scale, which measures the level of dependence in activities of daily living (0.75 vs. 0.15; p=0.001).
- In the multivariate analysis, patients with headache had a lower mortality of death (OR=0.39, 95%CI: 0.17-0.88, 95%CI: 0.17-0.88; p=0.007).
- Variables associated with headache in the multivariate analysis: anosmia, arthralgia, age, female sex, fever, myalgia, increased C-reactive protein level on admission, Rankin scale score, abnormal platelet count on admission, presence of lymphopenia on admission, elevated D-dimer level on admission, and high international normalized index during hospitalization.

---

aOR: adjusted odds ratio; CI: confidence interval; IQR: interquartile range; NR: not reported; OR: odds ratio; Q-SIT: Quick Smell Identification Test; SNOT-22: SinoNasal Outcome Test 22; UK: United Kingdom; US: United States of America.
* Data collection via internet or mobile applications.
† Cross-sectional study.
‡ Case-control study.
** Cohort study.
Source: Own elaboration.
Discussion

The articles retrieved describe the neurological manifestations that were associated with COVID-19 during a 6-month period following the WHO declaration of the pandemic. The main findings of these studies are presented below by type of neurological manifestation.

Impaired sense of smell and taste

Most of the publications included in the present review report an impaired sense of smell and taste (43%). Moreover, evidence suggests that between 51% and 67% of patients with mild COVID-19 report impairment of these senses. However, only one study conducted in South Korea in 3191 patients reported the prevalence of acute anosmia or ageusia in 15.3% (n=488/3191) of patients in the early stages of COVID-19 and 15.7% (n=367/2342) of patients with asymptomatic-to-mild disease severity. It should be noted that the main limitation of this research is that it studied the complete impairment of these senses, omitting the review of partial alterations.

On the other hand, a lower prevalence of these disorders was observed in patients with moderate and severe COVID-19 (23%-40%, respectively), since most of the analytical studies reviewed reported that the presence of these neurological manifestations was significantly more frequent in young people, women, patients without comorbidities, and patients with mild COVID-19. Furthermore, the only publication suggesting that there might be a direct association between disease severity and olfactory impairment is the study by Vaira et al., in which a statistically significant correlation was found between the severity of olfactory or gustatory impairment and the presence of fever, altered oxygen saturation, and requirement for hospitalization in patients with severe SARS-CoV-2 infection.

Studies using standardized tools for measuring smell and taste impairment (such as the SinoNasal Outcome Test 22 [SNOT-22] and the Quick Smell Identification Test [Q-SIT]) confirm that COVID-19 patients experience these impairments more frequently than the general population. Likewise, these studies suggest that the duration of sensory impairment is proportional to its severity. These papers also report that smell and taste disorders cannot be objectively confirmed in 26-51% of the patients who report them.

Regarding the usefulness of smell and taste impairment as a marker for COVID-19, three aspects stand out. First, case-control studies clearly showed that these disorders are significantly more frequent in patients with COVID-19 than in the general population. Second, individuals who report the presence of smell and taste impairment are more likely to have COVID-19 if they also have other symptoms of infection; for example, Menni et al. report that smell and taste impairment, fatigue, persistent cough, and loss of appetite were significantly associated with SARS-CoV-2 infection. Thirdly, it has been reported that the main differential diagnosis in cases of sudden smell and taste impairment is nasal obstruction due to other causes, such as allergic rhinitis.

Concerning the onset and duration of symptoms, data are quite heterogeneous. The reviewed publications report that between 9% and 15% of patients presented anosmia as the first symptom of the disease. Also, most patients report partial smell and taste impairment and a recovery time of 10 to 14 days, although some cases may require up to 1 month to recover.

It is noteworthy that recovery seems to be related to the degree of smell and taste disorder, since patients with anosmia took longer to recover than those with hyposmia.
Likewise, a prolonged duration of these impairments could be associated with the severity of COVID-19; however, the correlation between the severity of smell and taste impairment and the severity of COVID-19 has not been clearly established.66 The most relevant aspects of this disorder are presented in Figure 2.

<table>
<thead>
<tr>
<th>Outstanding features of smell and taste impairment in COVID-19 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observed in 51-67% of the patients</td>
</tr>
<tr>
<td>More frequent in women and younger patients (not children), patients without comorbidities, and patients with mild COVID-19</td>
</tr>
<tr>
<td>First symptom in 9-15% of cases</td>
</tr>
<tr>
<td>Recovery for patients with partial impairment of these senses usually takes 10 to 14 days</td>
</tr>
<tr>
<td>Recovery of patients with severe impairment is usually longer (weeks to months)</td>
</tr>
<tr>
<td>The main differential diagnosis is nasal obstruction due to other causes, such as allergic rhinitis</td>
</tr>
</tbody>
</table>

**Figure 2.** Main findings on olfactory and gustatory impairment in COVID-19 patients. Source: Own elaboration.

**Peripheral nerve involvement**

Sixteen articles (case studies and case series) were retrieved, reporting 20 COVID-19 patients with neuropathies, polyneuropathies, and polyradiculopathies. In general, these patients were younger than 60 years of age (only 7 were older) and had few comorbidities since only three of them had hypertension and one had paranoid schizophrenia (a 48-year-old man). Additionally, more than half of these patients had mild COVID-19, while only 3 had severe COVID-19, and no participant died. This may be related to the moment of neuropathy onset because, in most cases, the neuropathy occurred after the acute stage of the disease.

Regarding the type of neuropathy, most cases corresponded to Guillain-Barré syndrome (GBS) or one of its variants, and its onset occurred between 6 and 21 days after the onset of signs and symptoms; it was also reported that these neurological manifestations usually occurred after the onset of respiratory and systemic symptoms of COVID-19. This is consistent with reports in similar studies.90

Other types of neuropathy found were facial paralysis, hearing impairment, and supranuclear ophthalmoplegia. In general, the prognosis of patients with peripheral nerve involvement was good and chronic symptoms were reported in only one case. This case involved a 72-year-old man who had had mild COVID-19 (which manifested only with diarrhea) and whose comorbidities included hypertension, coronary artery disease, and alcoholism. This patient presented a very severe form of GBS and dysautonomia and had an unfavorable progression, requiring tracheostomy and percutaneous endoscopic gastrostomy tube placement.28
Headache

While only one of the retrieved analytical articles focuses on investigating the association between headache and COVID-19, 11 publications report data on this symptom (Table 3). In 8 of them, the prevalence of headache in patients with COVID-19 exceeds 50% and even reaches 82%. Importantly, most of these patients had mild SARS-CoV-2 infection. In fact, prevalence data below 50% is for patients with moderate and severe disease.

Despite the above, headache is considered a nonspecific symptom and is not included in the items considered in the diagnostic algorithms for COVID-19. In general terms, this symptom seems to be more frequent in women and in patients with a history of primary headache.

Distribution of neurological manifestations at different age ranges

The behavior of neurological manifestations in patients with SARS-CoV-2 infection had a different distribution across extremes of age. One of the conditions presenting in elderly patients is delirium. In the case reports and case series in which this disorder was reported, all patients (n=8) were older than 65 years and, at the same time, they had more comorbidities than the patients described in the other case reports included in the present review. In addition, half of these patients had mild COVID-19 (n=4), but it is striking that 3 of these participants had dementia and the other had paranoid schizophrenia. These findings confirm that patients with dementia, even if they have mild COVID-19, are at increased risk of developing delirium. Moreover, case reports reporting data on symptoms of delirium or mental confusion indicate that these symptoms appeared within the first four days from the onset of disease symptoms, suggesting that delirium may be an early neurological manifestation in older adults.

On the other hand, it was found that the presence of delirium is a marker for poor prognosis in older adults with severe COVID-19. In this regard, in the study by Helms et al., patients with delirium required invasive mechanical ventilation for a longer time and had a longer stay in the intensive care unit (ICU) than those without delirium and with a normal neurological examination.

At the other extreme of age, very few articles reported data on pediatric patients, which is a limitation for the representativeness of all population groups. On this point, only four of the publications reviewed explicitly refer to children; actually, being of legal age is one of the inclusion criteria in most of the studies reviewed. In particular, two of the four articles report smell and taste impairment. On the one hand, in the study by Somekh et al., in which 31 of the patients were between 5 and 17 years of age, it was found that these symptoms were less frequent in this age group (children: 26%; adults: 71%). On the other hand, in the United Kingdom, Mak et al. described three cases of adolescents between 14 and 17 years of age with COVID-19 who presented loss of smell and/or taste.

The other two articles are individual case reports. The first reports the case of a previously healthy 11-year-old boy who presented status epilepticus and was subsequently diagnosed with encephalitis based on the findings of cerebrospinal fluid analysis. Based on what was reported, the patient tested positive for COVID-19 as well as for rhinovirus/enterovirus on nasal swab test, although no evidence of the latter was found in this fluid, and finally, the child recovered completely in 6 days without the need for treatment.

The second reports a case of COVID-19-associated rhabdomyolysis in a 16-year-old patient with autism spectrum disorder, attention deficit hyperactivity disorder, morbidity...
obesity, obstructive sleep apnea, and eczema. According to this report, the patient, who tested positive for COVID-19, presented with myalgia, fever, mild shortness of breath, and dark-colored urine, and his creatine phosphokinase level was 427 656U/L, leading to a diagnosis of rhabdomyolysis. Finally, the child progressed satisfactorily during hospitalization and was discharged after 12 days with creatine phosphokinase levels of 6526U/L.45

Severe neurological manifestations

In addition to severe forms of GBS and cases of delirium that were associated with extubation difficulties and longer ICU stay, other severe neurological manifestations associated with COVID-19 have been described. Although the case of a pediatric patient with encephalitis was mentioned above, inflammatory involvement of the central nervous system was also reported in five other patients in the publications reviewed. Of these, a case of acute disseminated encephalomyelitis following SARS-CoV-2 infection in a 64-year-old woman with hypertension and vitiligo stands out.42 Also, 3 patients between 35 and 59 years of age (2 with severe COVID-19 and 1 with mild COVID-19) were reported to have encephalitis in the second week after symptom onset.37-39 It is noteworthy that only 1 of these 3 patients had comorbidities and, in fact, was the only one who died.

Likewise, a series of three cases of patients aged 33, 77 and 55 years of age with mild COVID-19 from the United States, who were admitted to the emergency department due to clinical symptoms of stroke, was retrieved. In these three cases, internal carotid artery thrombosis was documented.60

In addition, epileptic seizures associated with SARS-CoV-2 infection were reported in 6 patients, of whom 1 had severe infection and 2 had a previous diagnosis of epilepsy.32,33,35,36,64 In 5 of these patients, the onset of seizures was focal, while in the other one it was described as generalized tonic-clonic. In turn, 4 of the 6 patients presented status epilepticus, of which 2 had de novo status epilepticus, 1 had sequelae of herpetic encephalitis, and the other had thrombosis of the venous sinuses requiring craniotomy. Besides epileptiform activity, electroencephalogram monitoring reported encephalopathic tracing and graphoelements, such as periodic lateralized epileptiform discharges.

Other non-epileptic paroxysmal disorders were also described in some patients. The occurrence of vasovagal syncope was reported in 5 patients, most of whom were over 65 years of age,34,65 and only 1 of them reported the presence of convulsive epileptic seizures associated with vasovagal syncope, as well as autonomic dysfunction.34 Finally, a series of three patients with generalized non-epileptic myoclonus, similar to the startle reflex, was interpreted as a para-infectious immune-mediated disorder.63 None of the patients with vasovagal syncope or myoclonus had severe COVID-19.

Regarding the limitations of this literature review, two aspects should be mentioned that could have affected the inclusion of all the articles published on this topic in the period analyzed.

First, there is an underreporting of clinical manifestations that may be interpreted as general manifestations, but which, in other contexts, may be considered neurological. Such is the case of symptoms like myalgias, which are not the main objective of any of the articles retrieved, but are reported in at least 12 of the patients described, of which only 3 presented rhabdomyolysis.16,17,23,35,37,44-47,50,63,64 In addition, some of the descriptive articles reviewed report prevalence figures of myalgia in patients with COVID-19 between 25% and 57%,84,86,89 which is similar to those described in patients with headache, as mentioned above.
Second, some articles may not have been identified because, although they address this topic, they do not meet the parameters of the proposed search strategy, for example, those that do not include the selected keywords. Despite the above, the results obtained in this literature review allow us to establish an overview of the neurological manifestations in patients with COVID-19 infection.

Conclusions

In the six months following the declaration of the COVID-19 pandemic, multiple articles were published reporting data on the spectrum of neurological manifestations associated with SARS-CoV-2 infection. The search, review and analysis of these studies provided a general overview and led to the conclusion that, although the main involvement of COVID-19 is pulmonary, the nervous system can also be affected directly or indirectly. While taste and smell impairment is the most studied and reported neurological manifestation, a wide number of such manifestations were found to be associated with the disease.

Some of these neurological manifestations, such as headache and myalgia, are underreported because they are considered general symptoms and signs of the disease. However, other more specific manifestations such as epileptic seizures, peripheral nerve inflammation, encephalitis, delirium, and stroke have been described. Most of them do not seem to be related to the patient’s previous health condition or to the severity of COVID-19. Furthermore, other neurological manifestations such as delirium and epileptic seizures may be more frequent in patients with a history of dementia and epilepsy, respectively. Finally, it has been reported that the prognosis of patients with these neurological manifestations is usually favorable, except in those with conditions that cause sequelae, such as GBS or stroke. Future research is expected to better characterize the mechanisms underlying nervous system involvement in patients with COVID-19.

Conflicts of interest

None stated by the authors.

Funding

None stated by the authors.

Acknowledgments

None stated by the authors.

References


